法尼甾体X受体
CISH公司
状态5
化学
细胞因子
兴奋剂
癌症研究
下调和上调
细胞生物学
交易激励
转录因子
信号转导
生物
受体
核受体
基因表达
生物化学
免疫学
基因
原位杂交
作者
Zhizhen Xu,Gang Huang,Wei Gong,Yuanyin Zhao,Peng Zhou,Yijun Zeng,Fengtian He
标识
DOI:10.1089/jir.2012.0008
摘要
Cytokine inducible SH2-containing protein (CISH), which negatively regulates cytokine signaling by inhibiting JAK2/STAT5 activity, is regarded as a therapeutic target for inflammatory diseases. Farnesoid X receptor (FXR), a ligand-activated transcription factor, has been proposed to play a protective function in the inflammatory responses. However, the role of FXR in modulation of CISH expression is unknown. In the present study, we for the first time identified that in human hepatoma cell line HepG2 the activation of FXR by the natural agonist chenodeoxycholic acid (CDCA) and the synthetic specific agonist GW4064 upregulated CISH at both transcriptional and translational levels, and inhibited interleukin (IL)6-induced STAT5 activation. Moreover, the in vivo experiment demonstrated that gavaging mice with CDCA increased CISH expression and reduced basal STAT5 phosphorylation in liver tissues. Reporter assay showed that FXR agonists enhanced the transcriptional activity of CISH promoter. These data suggest that FXR may serve as a novel molecular target for manipulating CISH expression in hepatocytes. FXR-mediated upregulation of CISH may play an important role in the homeostasis of cytokine signal networks and be beneficial to control cytokine-associated inflammatory diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI